Mylan spars with agency over status of US manufacturing probe
This article was originally published in Scrip
Executive Summary
Mylan Laboratories held firm its view during its second-quarter earnings conference call that recent allegations of misconduct at its West Virginia manufacturing plant put forward in a news story in the Pittsburgh Post-Gazette are unfounded and that an FDA probe into possible problems at the plant had been closed, with no further issues. Statements by the agency have conflicted with that view, causing volatility in Mylan's share price.